-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 1,604 Shares
Nuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 1,604 Shares
Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) insider Darlene Noci sold 1,604 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $17.03, for a total value of $27,316.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Darlene Noci also recently made the following trade(s):
Get Nuvalent alerts:- On Friday, July 15th, Darlene Noci sold 3,782 shares of Nuvalent stock. The stock was sold at an average price of $17.29, for a total value of $65,390.78.
- On Monday, July 18th, Darlene Noci sold 100 shares of Nuvalent stock. The stock was sold at an average price of $17.07, for a total value of $1,707.00.
- On Thursday, July 7th, Darlene Noci sold 16,800 shares of Nuvalent stock. The stock was sold at an average price of $17.61, for a total value of $295,848.00.
Nuvalent Trading Down 3.4 %
Shares of Nuvalent stock opened at $16.88 on Friday. The business's fifty day simple moving average is $15.47 and its 200 day simple moving average is $13.34. Nuvalent, Inc. has a 12 month low of $7.09 and a 12 month high of $40.82.
Nuvalent (NASDAQ:NUVL – Get Rating) last posted its earnings results on Wednesday, August 10th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. On average, sell-side analysts predict that Nuvalent, Inc. will post -1.73 earnings per share for the current year.Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Nuvalent by 115.6% during the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after purchasing an additional 877,835 shares during the last quarter. Fairmount Funds Management LLC grew its position in Nuvalent by 46.3% in the first quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock worth $18,590,000 after acquiring an additional 423,779 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvalent by 9,445.3% in the fourth quarter. JPMorgan Chase & Co. now owns 391,645 shares of the company's stock worth $7,457,000 after purchasing an additional 387,542 shares during the last quarter. BlackRock Inc. lifted its stake in Nuvalent by 30.2% in the first quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock worth $17,466,000 after purchasing an additional 291,821 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Nuvalent during the second quarter valued at approximately $3,523,000.
Wall Street Analyst Weigh In
Separately, BMO Capital Markets assumed coverage on Nuvalent in a research report on Thursday, June 23rd. They issued an "outperform" rating and a $28.00 target price for the company.
Nuvalent Company Profile
(Get Rating)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
Featured Stories
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) insider Darlene Noci sold 1,604 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $17.03, for a total value of $27,316.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.
新价公司(纳斯达克代码:NUVL-GET Rating)内部人士Darlene Noci在8月24日星期三的一笔交易中出售了1,604股该股。这只股票的平均售价为17.03美元,总价值为27,316.12美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个链接获得。
Darlene Noci also recently made the following trade(s):
达琳·诺奇最近还进行了以下交易:
- On Friday, July 15th, Darlene Noci sold 3,782 shares of Nuvalent stock. The stock was sold at an average price of $17.29, for a total value of $65,390.78.
- On Monday, July 18th, Darlene Noci sold 100 shares of Nuvalent stock. The stock was sold at an average price of $17.07, for a total value of $1,707.00.
- On Thursday, July 7th, Darlene Noci sold 16,800 shares of Nuvalent stock. The stock was sold at an average price of $17.61, for a total value of $295,848.00.
- 7月15日,星期五,Darlene Noci出售了3,782股新价位股票。这只股票的平均售价为17.29美元,总价值为65,390.78美元。
- 7月18日,星期一,Darlene Noci出售了100股新价位股票。这只股票以17.07美元的平均价格出售,总价值为1707.00美元。
- 7月7日,星期四,Darlene Noci出售了16,800股新价位股票。这只股票的平均售价为17.61美元,总价值为295,848.00美元。
Nuvalent Trading Down 3.4 %
新价交易下跌3.4%
Shares of Nuvalent stock opened at $16.88 on Friday. The business's fifty day simple moving average is $15.47 and its 200 day simple moving average is $13.34. Nuvalent, Inc. has a 12 month low of $7.09 and a 12 month high of $40.82.
上周五,Nuvalal的股票开盘报16.88美元。该业务的50日简单移动均线切入位为15.47美元,200日简单移动均线切入位为13.34美元。Nuvality,Inc.的12个月低点为7.09美元,12个月高位为40.82美元。
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Nuvalent by 115.6% during the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after purchasing an additional 877,835 shares during the last quarter. Fairmount Funds Management LLC grew its position in Nuvalent by 46.3% in the first quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock worth $18,590,000 after acquiring an additional 423,779 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvalent by 9,445.3% in the fourth quarter. JPMorgan Chase & Co. now owns 391,645 shares of the company's stock worth $7,457,000 after purchasing an additional 387,542 shares during the last quarter. BlackRock Inc. lifted its stake in Nuvalent by 30.2% in the first quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock worth $17,466,000 after purchasing an additional 291,821 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Nuvalent during the second quarter valued at approximately $3,523,000.
对冲基金和其他机构投资者最近买卖了该公司的股票。先锋集团(Vanguard Group Inc.)在第一季度增持了115.6%的纽瓦利股份。先锋集团现在持有1,637,507股该公司股票,价值22,745,000美元,在上个季度又购买了877,835股。Fairmount Funds Management LLC在第一季度将其在Nuvality的头寸增加了46.3%。Fairmount Funds Management LLC在上个季度增持了423,779股后,现在拥有1,338,393股该公司股票,价值18,590,000美元。摩根大通在第四季度增持了9,445.3%的Nuvality股份。摩根大通公司目前持有391,645股该公司股票,价值7,457,000美元,上个季度又购买了387,542股。贝莱德股份有限公司在第一季度增持了纽瓦利30.2%的股份。贝莱德股份有限公司在上个季度增持了291,821股后,现在持有1,257,463股该公司股票,价值17,466,000美元。最后,千禧管理有限责任公司在第二季度购买了价值约3,523,000美元的新股份。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, BMO Capital Markets assumed coverage on Nuvalent in a research report on Thursday, June 23rd. They issued an "outperform" rating and a $28.00 target price for the company.
另外,蒙特利尔银行资本市场在6月23日(星期四)的一份研究报告中承担了对Nuvalal的报道。他们对该公司的评级为“跑赢大盘”,目标价为28.00美元。
Nuvalent Company Profile
新价公司简介
(Get Rating)
(获取评级)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
新价公司是一家临床阶段的生物制药公司,为癌症患者开发疗法。其主要候选产品有NVL-520,这是一种脑穿透性ROS1选择性抑制剂,用于抑制ROS1融合,这种融合表达正常的ROS1激活域,没有任何耐药突变,并且在存在对已批准和正在研究的ROS1抑制剂产生耐药性的突变时仍保持活性,该药处于I期开发中;以及NVL-655,一种脑渗透性ALK选择性抑制剂,用于解决紧急治疗耐药性、中枢神经系统相关不良事件和脑转移等临床挑战,这些挑战可能限制正在进行I/II期临床试验的第一、第二和第三代ALK抑制剂的使用。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- 免费获取StockNews.com关于Nuvalal的研究报告(NUVL)
- Dollar General的拉力赛有三个理由
- Salesforce股票在盈利后可能具有长期潜力
- 艾伯维公司。应该在你的股息投资组合中占有一席之地吗?
- PayPal是盈利后价格跳涨后的买入吗?
- 威廉姆斯-索诺马的高端消费者仍在消费
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《新价日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Nuvalal及相关公司评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧